Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07109414 · ClinicalTrials.gov registry record · Phase 2

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

A Phase 2 study of Platinum-resistant Ovarian Cancer, sponsored by Novita Pharmaceuticals.

Active
Registry status
Phase 2
Development phase
380
Enrollment target
6
Study locations

NCT07109414 is a Phase 2 study of Platinum-resistant Ovarian Cancer that is active but no longer recruiting, run by Novita Pharmaceuticals. The registered enrollment target is 380 participants, above the 164-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (132% higher). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07109414, a Phase 2 study of Platinum-resistant Ovarian Cancer, is active but no longer recruiting, sponsored by Novita Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
380 participants
Enrollment target
6
Study locations

Study Summary

The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs. PLD alone in participants with platinum-resistant ovarian cancer (PROC).

Conditions Studied

Platinum-resistant Ovarian Cancer

Interventions

  • DRUG PLD
  • DRUG NP-G2-044

Study Locations (6)

Arizona

  • HonorHealth Cancer Care - Phoenix

Louisiana

  • Trials365 - Shreveport

New Mexico

  • Optimum Clinical Research Group, LLC - Albuquerque

Pennsylvania

  • University of Pennsylvania Health System, Perelman Center for Advanced Medicine - Philadelphia

Utah

  • Utah Cancer Specialists - Salt Lake City

Wisconsin

  • University Of Wisconsin Carbone Cancer Center - Madison

Trial Details

FieldValue
Enrollment Target 380 participants
Start Date 2025-12-29
Est. Completion 2029-10-24
Phase Phase 2

Sponsor

Novita Pharmaceuticals

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07109414

The ClinicalTrials.gov registry entry for NCT07109414 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 164-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (132% higher). The listed sponsor is Novita Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Platinum-resistant Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which PLD is the first listed.

NCT07109414 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, Louisiana, New Mexico.

Frequently Asked Questions

What is clinical trial NCT07109414 about?

NCT07109414 is a clinical study titled "Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)". The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs. PLD alone in participants with platinum-resistant ovarian cancer (PROC).

What is the current status of trial NCT07109414?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 380 participants. The study started on 2025-12-29. Estimated completion is 2029-10-24.

What conditions does trial NCT07109414 study?

This clinical trial studies the following conditions: Platinum-resistant Ovarian Cancer.

What interventions are being tested in trial NCT07109414?

The interventions under investigation include: PLD (DRUG), NP-G2-044 (DRUG).

Who is sponsoring clinical trial NCT07109414?

This trial is sponsored by Novita Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07109414 being conducted?

This trial has 6 study locations across Arizona, Louisiana, New Mexico, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Platinum-resistant Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Platinum-resistant Ovarian Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.